Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies
Background: Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein
convertase subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol …
convertase subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol …
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long …
MJ Koren, RP Giugliano, FJ Raal, D Sullivan… - Circulation, 2014 - Am Heart Assoc
Background—Evolocumab (AMG 145), a monoclonal antibody against proprotein
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …
EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European heart …, 2014 - academic.oup.com
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott… - … England Journal of …, 2015 - Mass Medical Soc
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
Long-term low-density lipoprotein cholesterol–lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years …
MJ Koren, MS Sabatine, RP Giugliano… - JAMA …, 2017 - jamanetwork.com
Importance The Open-Label Study of Long-term Evaluation Against LDL-C (OSLER-1)
evaluated the durability of long-term efficacy and safety during long-term therapy with …
evaluated the durability of long-term efficacy and safety during long-term therapy with …
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech… - New England journal …, 2017 - Mass Medical Soc
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
[HTML][HTML] A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American journal of …, 2016 - Elsevier
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
Evolocumab: a review in hyperlipidemia
GM Keating - American Journal of Cardiovascular Drugs, 2016 - Springer
Evolocumab (Repatha®) is a monoclonal antibody targeting proprotein convertase
subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously at a dosage of 140 mg …
subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously at a dosage of 140 mg …
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
GK Hovingh, FJ Raal, R Dent, C Stefanutti… - Journal of clinical …, 2017 - Elsevier
Background Evolocumab, a fully human monoclonal antibody against proprotein convertase
subtilisin/kexin type 9, is safe and effective when dosed biweekly (Q2W) or monthly (QM) in …
subtilisin/kexin type 9, is safe and effective when dosed biweekly (Q2W) or monthly (QM) in …